116 related articles for article (PubMed ID: 19649941)
1. Regulation of pre-mRNA splicing by antisense oligonucleotides.
Taylor JK; Dean NM
Curr Opin Drug Discov Devel; 1999 Mar; 2(2):147-51. PubMed ID: 19649941
[TBL] [Abstract][Full Text] [Related]
2. Modification of pre-mRNA splicing by antisense oligonucleotides.
Kole R
Acta Biochim Pol; 1997; 44(2):231-7. PubMed ID: 9360712
[TBL] [Abstract][Full Text] [Related]
3. RNA modulation, repair and remodeling by splice switching oligonucleotides.
Kole R; Williams T; Cohen L
Acta Biochim Pol; 2004; 51(2):373-8. PubMed ID: 15218534
[TBL] [Abstract][Full Text] [Related]
4. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos.
Morcos PA
Biochem Biophys Res Commun; 2007 Jun; 358(2):521-7. PubMed ID: 17493584
[TBL] [Abstract][Full Text] [Related]
5. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
7. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C
Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459
[TBL] [Abstract][Full Text] [Related]
8. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
[TBL] [Abstract][Full Text] [Related]
9. Antisense effects in the cell nucleus: modification of splicing.
Kole R; Sazani P
Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345
[TBL] [Abstract][Full Text] [Related]
10. Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.
Resina S; Kole R; Travo A; Lebleu B; Thierry AR
J Gene Med; 2007 Jun; 9(6):498-510. PubMed ID: 17471591
[TBL] [Abstract][Full Text] [Related]
11. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice.
Roberts J; Palma E; Sazani P; Ørum H; Cho M; Kole R
Mol Ther; 2006 Oct; 14(4):471-5. PubMed ID: 16854630
[TBL] [Abstract][Full Text] [Related]
12. Dystrophin nonsense mutations can generate alternative rescue transcripts in lymphocytes.
Nishiyama A; Takeshima Y; Zhang Z; Habara Y; Tran TH; Yagi M; Matsuo M
Ann Hum Genet; 2008 Nov; 72(Pt 6):717-24. PubMed ID: 18652600
[TBL] [Abstract][Full Text] [Related]
13. Splice-switching antisense oligonucleotides as therapeutic drugs.
Havens MA; Hastings ML
Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
[TBL] [Abstract][Full Text] [Related]
14. Splice-switching efficiency and specificity for oligonucleotides with locked nucleic acid monomers.
Guterstam P; Lindgren M; Johansson H; Tedebark U; Wengel J; El Andaloussi S; Langel U
Biochem J; 2008 Jun; 412(2):307-13. PubMed ID: 18271753
[TBL] [Abstract][Full Text] [Related]
15. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of antisense-mediated exon skipping.
van Ommen GJ; van Deutekom J; Aartsma-Rus A
Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
[TBL] [Abstract][Full Text] [Related]
17. Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing.
Chen HY; Kathirvel P; Yee WC; Lai PS
Gene Ther; 2009 Feb; 16(2):211-7. PubMed ID: 18923454
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of splice-switching oligonucleotides.
Bauman J; Jearawiriyapaisarn N; Kole R
Oligonucleotides; 2009 Mar; 19(1):1-13. PubMed ID: 19125639
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II.
Matos L; Gonçalves V; Pinto E; Laranjeira F; Prata MJ; Jordan P; Desviat LR; Pérez B; Alves S
Biochim Biophys Acta; 2015 Dec; 1852(12):2712-21. PubMed ID: 26407519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
